Adamas to Present at Upcoming HC Wainwright Conference
September 08 2020 - 4:05PM
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to
developing and delivering medicines that make a meaningful
difference to people affected by neurological diseases, today
announced that Neil F. McFarlane, the Company’s Chief Executive
Officer, is scheduled to present at the H.C. Wainwright 22nd Annual
Global Investment Conference on Tuesday, September 15th at 12:30 pm
Eastern Time (9:30 am Pacific).
The presentation will be webcast live from the
investor relations section of the Adamas website at
http://ir.adamaspharma.com/events-presentations. An archived
version of the webcast will be available via replay for 30 days
following the presentation.
About Adamas Pharmaceuticals,
Inc.At Adamas our vision is clear – to deliver innovative
medicines that reduce the burden of neurological diseases on
patients, caregivers and society. We are a fully integrated company
focused on growing a portfolio of therapies to address a range of
neurological diseases. In 2018, Adamas successfully launched
GOCOVRI® (amantadine) extended-release capsules, the first and only
FDA-approved medicine for the treatment of dyskinesia in patients
with Parkinson’s disease receiving levodopa-based therapy, with or
without concomitant dopaminergic medications. GOCOVRI is also the
only medicine clinically proven to reduce both dyskinesia and OFF.
For more information, please visit www.adamaspharma.com.
Contact:
Investors: Peter VozzoManaging Director,
Westwicke443-213-0505peter.vozzo@westwicke.com
Media: Sarah MathiesonVice President of
Corporate Communications510-450-3528smathieson@adamaspharma.com
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Jul 2023 to Jul 2024